BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
But looking at, there have been a couple combination trials now, right? So the Sunrise 1, looking initially with a citrelumab plus tar, and then you have data with creatostimogene in combination with PEMBRO. I think that, and then, of course, we had the PEMBRO data alone, which To me, that doesn't seem to be the primary direction that people are going.
0
💬
0
Comments
Log in to comment.
There are no comments yet.